SYNLOGIC, INC.
SYNLOGIC, INC. (SYBX): 4 pipeline candidates · ~76 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
75.9 months
6% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for SYNLOGIC, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.3M
Cash
$14.1M
Quarterly Burn
$563K
Runway
75.9 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| labafenogene marselecobac | Phase 3 |
| synb1353 | Phase 1 |
| synb2081 | Preclinical |
| synb8802 | Phase 1 |
Frequently asked questions
How many drug candidates are in SYNLOGIC, INC.'s pipeline?
SYNLOGIC, INC. (SYBX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SYNLOGIC, INC.'s lead drug candidate?
SYNLOGIC, INC.'s most advanced tracked candidate is labafenogene marselecobac (Phase 3) for phenylketonuria (PKU).
What is SYNLOGIC, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SYNLOGIC, INC. has approximately 75.9 months of cash runway.
What is SYNLOGIC, INC.'s market capitalization?
SYNLOGIC, INC.'s market capitalization is approximately $8.3M.
Who is the CEO of SYNLOGIC, INC.?
Aoife M. Brennan is the chief executive officer of SYNLOGIC, INC. (SYBX).
Get the full picture on SYNLOGIC, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.